---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066374"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:16:32.697814+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MindMed reports Q1 cash $245.5M; Phase 3 trials on track for 2026 topline data

## Summary
- Cash and investments $245.5M at March 31, 2025; runway into 2027 and at least 12 months beyond first Phase 3 readout.
- Dosed first patient in Phase 3 Emerge study of MM120 ODT for MDD; topline data expected 2H 2026.
- Enrollment on track in Phase 3 Voyage and Panorama studies for GAD; topline data 1H 2026 (Voyage) and 2H 2026 (Panorama).
- Amended K2 HealthVentures loan: up to $120M available, received ~$17.8M net cash, interest-only period extended through May 1, 2027.

## SEC filing metadata
- accession: 0000950170-25-066374
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017025066374/0000950170-25-066374-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017025066374/mnmd-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066374
- JSON: https://secwatch.observer/filing/0000950170-25-066374.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066374.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.